CAS: 124750-51-2; 5-(4'-(Bromomethyl)-[1,1'-Biphenyl]-2-yl)-1-Trityl-1H-Tetrazole

相似化合物

133051-88-4 124750-51-2 358685-13-9

上下游产品

CAS号124750-53-4 N-(三苯基甲基)-5-(4'... | CAS号114772-53-1 2-氰基-4'-甲基联苯 | CAS号2042-37-7 邻溴苯腈 | CAS号120568-11-8 5-[2-(4'-甲基联苯基)]四唑 | CAS号611-20-1 水杨腈 | CAS号624-31-7 对碘甲苯 | CAS号76-83-5 三苯基氯甲烷 | CAS号31614-66-1 tributyl(p-toly... | CAS号5720-05-8 对甲基苯基硼酸 | CAS号761404-85-7 三苯甲基奥美沙坦 | CAS号124751-00-4 [2-丁基-4-氯-1-[(2... | CAS号138402-10-5 三苯甲基依贝沙坦 | CAS号144689-63-4 奥美沙坦酯 | CAS号154709-18-9 Olmesartan impurity | CAS号144690-92-6 三苯甲基奥美沙坦酯 | CAS号137862-53-4 缬沙坦 | CAS号144690-33-5 4-(1-羟基-1-甲基乙基)... | CAS号120568-18-5 N-三苯甲基氯沙坦甲醛

4,4-Dimethyl-2-(4'-Methylbiphenyl-2-yl)Oxazoline置于盐酸,N-溴代丁二酰亚胺(Nbs),氯化亚砜,叠氮基三甲基硅烷,N,N-二异丙基乙胺,三苯基膦,Sodium Hydroxide,偶氮二甲酸二乙酯体系中,用 四氢呋喃,甲醇,四氯化碳,水 用作溶剂,化学反应生成N-(三苯基甲基)-5-(4'-溴甲基联苯-2-基)四氮唑
参考文献:1,(3,)5-Substituted Imidazoles,Useful In The Treatment Of Hypertension And Methods For Their Preparation
标题:1,(3,)5-Substituted Imidazoles,Useful In The Treatment Of Hypertension And Methods For Their Preparation

专利信息

专利号:EP-1546135-B1
优先权日:2002-07-16
标题:Novel synthesis of irbesartan
发明人：NISNEVICH GENNADY; RUKHMAN IGOR; PERTSIKOV BORIS; KAFTANOV JULIA; DOLITZKY BEN-ZION
权利人:TEVA PHARMA
摘要:Provided is a novel synthesis of irbesartan employing a phase transfer catalyst. Also provided is irbesartan having a fine particle size.

专利号:US-7312340-B2
优先权日:2003-02-05
标 题:Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one
发明人：DOLITZKY BEN-ZION; KAFTANOV JULIA; PERTSIKOV BORIS; RUKHMAN IGOR; NISNEVICH GENNADY
权利人:TEVA PHARMA
摘要:Provided is a novel method of making 2-butyl-3-[[2′(1-trityl-1H-tetrazol-5-yl)biphen-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-ene-4-one, which can be converted to irbesartan. Also provided are methods of making irbesartan.

专利号:WO-2006038223-A1
优先权日:2004-10-06
标题:A process for preparation of 2-n-butyl -4-chloro - 1 - {[2`- (2-triphenylmethyl - 2h - tetrazole - 5- yl) - 1, 1’ - biphenyl-4-yl] methyl}-lh- imidazoie-5-methanol (intermediate of losartan)
发明人：CHAVA SATYANARYANA; VASIREDDY UMAMAHESWAR RAO; VELLANKI SIVA RAM PRASAD; BALUSU RAJABABU
权利人:MATRIX LAB LTD; CHAVA SATYANARYANA; VASIREDDY UMAMAHESWAR RAO; VELLANKI SIVA RAM PRASAD; BALUSU RAJABABU
摘要:The present invention relates to a process for preparation of N-substituted heterocyclic derivative,2-n-Butyl-4-chloro- 1 - { [2' -(2-triphenylmethyl-2H-tetrazole-5-yl)- 1,1' -biphenyl -4-yl] methyl} -lH-imidazole-5-methanol, an important intermediate in the synthesis of Losartan and its pharmaceutically acceptable salts using phase transfer catalyst and minimal number of solvents with improved yield.

专利号:EP-1831186-B1
优先权日:2004-11-30
标题:A process for the synthesis of valsartan
发明人：ZUPANCIC SILVO; PECAVAR ANICA; ZUPET ROK
权利人:KRKA D D NOVO MESTO
摘要:This invention relates to an improved process for preparing a valsartan, or a pharmaceutically acceptable salt thereof, or pharmaceutical preparation containing either entity wherein a compound of formula (II) nor a salt thereof, is reacted with valine or an ester or a salt thereof in a solvent selected from the group consisting of methylene chloride, chloroform, butyl chloride, isopropyl acetate and tert -butyl methyl ether to form a compound of formula (IV) nwhich is then acylated to form a compound of formula (VI) nwherein R is hydrogen, alkyl, alkenyl or benzyl; which is then deprotected to give valsartan, and may be converted to a pharmaceutically acceptable salt and/or a pharmaceutical formulation. The invention also covers intermediates of formula (IV) and (VI) wherein R=H.

专利号:US-2006128967-A1
优先权日:2003-02-05
标 题:Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one

专利号:US-7906501-B2
优先权日:2004-04-28
标题:Pyrrole derivatives with angiotensin II antagonist activity
发明人：MAKOVEC FRANCESCO; ARTUSI ROBERTO; GIORDANI ANTONIO; ZANZOLA SIMONA; ROVATI LUCIO CLAUDIO
权利人:ROTTAPHARM SPA
摘要:Compounds which may be represented by the general formula (I) shown below and in which: R 1 is a group independently selected from among: CHO, —COOH, —CH 2 OH R 2 is hydrogen or a linear or branched C 1 -C 6 alkyl group R 3 is hydrogen or a halogen group selected from among Cl and Br R 4 is a linear or branched C 3 -C 5 alkyl group and the pharmaceutically acceptable salts thereof such as the sodium or potassium salt. The compounds exhibit potent and selective All antagonist activity and are useful for the treatment of any disorders in which elevated synthesis of All or overexpression of the AT 1 receptor may play a primary pathological role, as in the case of arterial hypertension, congestive cardiac insufficiency, platelet aggregation and disorders associated therewith such as for example myocardial and cerebral infarction, renal ischaemia, venous and arterial thrombosis, peripheral vasculopathy, pulmonary hypertension, diabetes mellitus, diabetic neuropathy, glaucoma and diabetic retinopathy.